ClinicalTrials.gg
CompletedNCT00452348Updated Dec 9, 2016Results posted

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

A Phase 4 interventional study of Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID and Fluticasone propionate 250 mcg BID in Asthma, sponsored by GlaxoSmithKline. Completed at 81 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-12-09.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
20th of 146
628 · median 100
Started
2007
with 17 others
Phase 4
52 of 147
1 open now
Registered
33rd of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 20th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 33rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • FLOVENT
  • fluticasone
  • 12 month
  • salmeterol
  • asthma
  • ADVAIR
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects eligible for enrollment in the study must meet all of the following criteria:

    1. Consent: A signed and dated written must be obtained from the subject and/or subject's legally acceptable representative prior to study participation.
    2. Type of Subject: Outpatient
    3. Gender: Male or female Females are eligible to participate only if they are currently non-pregnant and non-lactating.

A female is eligible to enter and participate in the study if she is:

  1. of non-; OR
  2. of child-bearing potential but has a negative urinary pregnancy test at Screening (Visit 1 and when specified in Appendix 1) and agrees to take precautions (including abstinence) which are adequate to prevent pregnancy during the study.

    Acceptable methods of contraception [Hatcher, 2004] are:

    • Abstinence
    • oral contraceptive (either combined or progestogen only)
    • injectable progestogen
    • implants of levonorgestrel
    • estrogenic vaginal ring
    • percutaneous contraceptive devices
    • intrauterine device (IUD) or intrauterine system (IUS) with published data showing that the lowest expected failure rate is less than 1% per year
    • male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject
    • double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent

      1. Age: A subject must be 12 years of age at Visit 1 (screening).
      2. Asthma Diagnosis: A documented diagnosis of persistent asthma, for at least six months, as defined by the following American Thoracic Society definition:

    Asthma is a clinical syndrome characterized by increased responsiveness of the airways to a variety of stimuli. The major symptoms of asthma are episodes of dyspnea, wheezing, and cough, which may vary from mild and almost undetectable to severe and unremitting (status asthmaticus). The primary physiological manifestation of this hyperresponsiveness is variable airway obstruction. This can take the form of spontaneous fluctuations in the severity of obstruction, substantial improvements in the severity of obstruction following bronchodilators or , or increased obstruction caused by drugs or other stimuli [American Thoracic Society, 1987].

    1. Asthma Medication History: A subject must be using a low to medium dose of an ICS (Table 1) OR a combination of controller medications (Table 2), containing a low (total daily) dose ICS (as defined in Table 1) for at least 4 weeks preceding screening.

    Table 1 (ICS Dosage Table) Inhaled Corticosteroid (Dosage (mcg/day))(LowMedium) Beclomethasone dipropionate CFC (168 = 504> 504 = 840) Beclomethasone dipropionate HFA (80 = 240>240 = 640) Triamcinolone acetonide (400 = 1000>1000 = 2000) Flunisolide (500 = 1000> 1000 = 2000) Fluticasone propionate inhalation aerosol (176 = 220> 220 = 440) Fluticasone propionate inhalation powder (100 = 250> 250 = 500) Budesonide1 (200 = 600> 600 =1200) Mometasone (200 = 400> 400 = 800) Ciclesonide (80 = 160>160 = 320)

    1.Respules are allowed at a dosage of 250-500mcg/day.

    Table 2 (Asthma Controller Medications) Asthma Controller Medication(s) Low dose ICS + Leukotriene modifiers Low dose ICS + Theophylline products Low Dose ICS + Inhaled anticholinergics or combination products (e.g., Atrovent or Combivent) Low Dose ICS + Long acting inhaled anticholinergic (e.g. Spiriva) Low dose ICS+ long acting beta agonist or combination products containing a low dose ICS and a long-acting beta-agonists (e.g. ADVAIR™/SERETIDE™1 100/50 mcg BID or Symbicort 160/9 mcg BID (i.e 80/4.5 mcg two inhalations BID)

    1.ADVAIR/SERETIDE =250/50 mcg BID or Symbicort 320/9 mcg BID (i.e 160/4.5 mcg two inhalation BID) are not permitted.

    1. Pulmonary function: A pre-albuterol (salbutamol) of 50% and 85% of predicted normal value at screening (Visit 1) after withholding asthma medications as detailed in the protocol (Section 6.8.1). Predicted FEV1 will be based on the National Health and Nutrition Examination Survey (NHANES III) predicted normal values for ages 8 years and older [Hankinson, 1999].
    2. Reversibility: An increase in FEV1 of 12% over the pre-albuterol (salbutamol) FEV1 within 30 minutes after the inhalation of 2-4 puffs of albuterol (salbutamol). Historical documentation of reversibility will not be permitted.
    3. Asthma symptom criteria: Each subject must have experienced asthma symptoms requiring albuterol (salbutamol) use within the 4 weeks preceding screening (Visit 1).

    Specific information regarding warnings, precautions, , adverse events, and other pertinent information on the product that may impact subject eligibility is provided in the IB and the product labels.

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following criteria must not be enrolled in the study:

    1.Life-Threatening Asthma: A subject must not have life-threatening asthma. Life-threatening asthma is defined for this protocol as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures, or asthma-related syncopal episode(s) within the 12 months prior to screening (Visit 1).

    2.Worsening of Asthma: A subject must not have experienced a worsening of asthma which involved an ER visit, hospitalization or use of oral/parenteral within 4 weeks of screening (Visit 1).

    3.Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only intermittent or seasonal or exercise-induced asthma are excluded from participation in this study.

    4.Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.

    5.Concurrent Conditions/Diseases: A subject with historical or current evidence of any , co-morbid or uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.

The list of excluded conditions/diseases includes, but is not limited to:

congestive heart failure known aortic aneurysm clinically significant coronary clinically significant cardiac arrhythmia heart disease stroke within 3 months of screening (Visit 1) uncontrolled hypertension coronary artery disease hematologic, hepatic, or renal disease cystic fibrosis poorly controlled peptic ulcer dyspnea by any other cause than asthma gastroesophageal reflux disease (GERD) not controlled by pharmacotherapy and may be causing/contributing to subject's respiratory symptoms thyrotoxicosis hypokalemia immunologic compromise current malignancy1 tuberculosis (current or quiescent) Cushing's or Addison's disease pneumonia, pneumothorax, chronic bronchitis or atelectasis uncontrolled diabetes mellitus recent history of drug or alcohol abuse 1.history of is acceptable only if subject has been in remission for one year prior to screening (Visit 1; remission = no treatment for the malignancy in the 12 months prior to screening [Visit 1])

  1. Drug Allergy: A subject must not have had any immediate or delayed to any beta2-agonist; sympathomimetic drug; any intranasal; inhaled or systemic corticosteroid therapy; lactose; or have a severe milk protein allergy.
  2. Respiratory Tract Infections: A subject must not have had any sinus, middle ear, oropharyngeal, upper or lower respiratory tract infection symptoms that have not resolved at least 7 days immediately preceding screening (Visit 1).
  3. Asthma Medications: Asthma medications listed below must not have been used prior to screening (Visit 1) for the required exclusion period as indicated below:

    Medication (Exclusion Period Prior to screening (Visit 1)) Oral or parenteral systemic corticosteroids (4 weeks) Omalizumab (Xolair) (6 months)

<!-- -->

  1. Concurrent Medications: A subject must not have the concurrent use of any of the following medications that interact with any of the study drugs used in this study, or that may affect the course of asthma or interact with sympathomimetic amines, such as:

    • beta-adrenergic receptor blocking agents
    • monoamine oxidase (MAO) inhibitors
    • tricyclic antidepressants
    • ritonavir
    • ketoconazole
  2. Concurrent use of asthma medications: Concurrent use of all asthma medications (other than protocol defined study and rescue medications and oral/parenteral corticosteroids) are prohibited during the study.
  3. Concomitant use of leukotriene modifiers (LTM) for allergies is prohibited. A subject must not be on LTM for treatment of nasal allergies that requires regular maintenance therapy. Substitution with any other antihistamine is permitted.
  4. Medications: A subject must not be using, or require the use of, immunosuppressive medications during the study.
  5. Immunotherapy for the treatment of allergies is not allowed during the study unless the subject has used a constant dose for 4 weeks prior to Screening (Visit 1) and the same dose will be continued throughout the study.
  6. Tobacco Use: >10 pack year history or use of any tobacco products within 1 year of screening (Visit 1). This includes cigarettes, cigars, pipe, chewing tobacco, and snuff.
  7. Questionable Validity of Consent: A subject must not have any infirmity or disability that would limit the subject's consent.
  8. Positive Pregnancy Test (for all females who have had menarche): A current positive pregnancy test.
  9. Medications: A subject must not have had use of any investigational drug within 30 days of screening (Visit 1).
  10. Site Affiliation: A subject may not participate if he/she is a participating investigator, sub-investigator, study coordinator, employee of a participating investigator or is in any way associated with the administration of the study. Immediate family members of these individuals are also excluded.
  11. Compliance with Study Requirements: A subject may not participate if, in the opinion of the investigator, there are present or anticipated circumstances that will prohibit the subject from being compliant with study visits and procedures (e.g. geographic location that will prohibit subject from required clinic visit schedule).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
628 participants (actual)

Study arms

  • Active comparator
    Fluticasone propionate 250 mcg BID

    Fluticasone propionate 250 mcg BID

    Drug: Fluticasone propionate 250 mcg BID

  • Active comparator
    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

Interventions

  • DrugFluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

    Also known as: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID and Fluticasone propionate 250 mcg BID

  • Fluticasone propionate 250 mcg BID

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

    Time frame: Baseline and Week 1 through Week 52

Secondary outcomes

  1. Mean Change From Baseline in AM PEF Over Weeks 1-52

    Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

    Time frame: Baseline and Week 1 through Week 52

  2. Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52

    A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.

    Time frame: Baseline and Week 1 through Week 52

  3. Rate of Asthma Attacks Per Participant Per Year

    The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a \>=20% decrease in AM PEF, a \>=70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.

    Time frame: Week 1 through Week 52

07

Results

Posted Feb 15, 2010

Participant flow

Participant flow — Overall Study
MilestoneFSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
Started310318
Completed231234
Not completed7984
Withdrew: Adverse event69
Withdrew: Lack of efficacy109
Withdrew: Lost to follow-up148
Withdrew: Protocol violation2228
Withdrew: Withdrawal by subject1821
Withdrew: Other99

Outcome measures

PrimaryMean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52

Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

Time frame:
Baseline and Week 1 through Week 52
Reported as:
Mean · Liters
Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52
LitersFSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-520.16 ± 0.0170.12 ± 0.020
Statistical analysis
  • FSC DISKUS 250/50 mcg BID vs FP DISKUS 250 mcg BID for 52 Weeks · ANCOVA · p = 0.090 · Least squares mean: 0.04 · 95% CI -0.01 to 0.09
SecondaryMean Change From Baseline in AM PEF Over Weeks 1-52

Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

Time frame:
Baseline and Week 1 through Week 52
Reported as:
Mean · Liters/minute (L/min)
Mean Change From Baseline in AM PEF Over Weeks 1-52
Liters/minute (L/min)FSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
Mean Change From Baseline in AM PEF Over Weeks 1-5227.7 ± 2.8514.6 ± 2.49
SecondaryMean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52

A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.

Time frame:
Baseline and Week 1 through Week 52
Reported as:
Mean · Percentage of symptom-free days
Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52
Percentage of symptom-free daysFSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-5237.4 ± 2.0328.9 ± 1.82
SecondaryRate of Asthma Attacks Per Participant Per Year

The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a \>=20% decrease in AM PEF, a \>=70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.

Time frame:
Week 1 through Week 52
Reported as:
Mean · attacks per participant per year
Rate of Asthma Attacks Per Participant Per Year
attacks per participant per yearFSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
Rate of Asthma Attacks Per Participant Per Year2.63 (2.17 to 3.19)2.73 (2.26 to 3.31)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC DISKUS 250/50 mcg BID—7/310 (2.3%)184/310 (59.4%)
FP DISKUS 250 mcg BID for 52 Weeks—9/318 (2.8%)201/318 (63.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventFSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
CholelithiasisHepatobiliary disorders0/3102/318
Cardiac deathGeneral disorders1/3100/318
Ankle fractureInjury, poisoning and procedural complications1/3100/318
Breast cancerReproductive system and breast disorders1/3101/318
AnaemiaBlood and lymphatic system disorders1/3100/318
Atrial fibrillationCardiac disorders1/3100/318
Ovarian cystReproductive system and breast disorders1/3100/318
AsthmaRespiratory, thoracic and mediastinal disorders1/3100/318
Large intestine perforationGastrointestinal disorders0/3101/318
CholecystitisInfections and infestations0/3101/318
Most frequent other events
Most frequent other events
EventFSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 Weeks
NasopharyngitisInfections and infestations54/31070/318
HeadacheNervous system disorders51/31060/318
Upper respiratory tract infectionInfections and infestations45/31055/318
SinusitisInfections and infestations33/31040/318
BronchitisInfections and infestations34/31038/318
Back painMusculoskeletal and connective tissue disorders23/31024/318
Oropharyngeal painRespiratory, thoracic and mediastinal disorders23/31019/318
RhinitisInfections and infestations23/31018/318
InfluenzaInfections and infestations15/31021/318
CoughRespiratory, thoracic and mediastinal disorders19/31018/318

Baseline characteristics

Age, Continuous
Age, Continuous(years)FSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 WeeksTotal
Mean40.9 ± 15.7139.6 ± 16.5640.2 ± 16.15
Gender
Gender(Participants)FSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 WeeksTotal
Female186181367
Male124137261
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FSC DISKUS 250/50 mcg BIDFP DISKUS 250 mcg BID for 52 WeeksTotal
White254262516
African American292756
Asian202545
American Indian202
Other549
08

Study locations

81 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Fullerton, California 92835, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    Stockton, California 95207, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Pueblo, Colorado 81008, United States
  • GSK Investigational Site
    Hudson, Florida 34667, United States
  • GSK Investigational Site
    South Miami, Florida 33143, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Albany, Georgia 31707, United States
  • GSK Investigational Site
    Gainesville, Georgia 30501, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30045, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Coeur D'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Evansville, Indiana 47710, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Jefferson City, Missouri 65101, United States
  • GSK Investigational Site
    Missoula, Montana 59808, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68505, United States
  • GSK Investigational Site
    Papillion, Nebraska 68046, United States
  • GSK Investigational Site
    Ocean, New Jersey 07712, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Fargo, North Dakota 58104, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Collegeville, Pennsylvania 19426, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • GSK Investigational Site
    Cumberland, Rhode Island 02864, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Greer, South Carolina 29651, United States
  • GSK Investigational Site
    El Paso, Texas 79903, United States
  • GSK Investigational Site
    Houston, Texas 77070, United States
  • GSK Investigational Site
    Killeen, Texas 76542, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Murray, Utah 84107, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Gig Harbor, Washington 98335, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26505, United States
  • GSK Investigational Site
    Greenfield, Wisconsin 53228, United States
  • GSK Investigational Site
    Madison, Wisconsin 53972, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • GSK Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • GSK Investigational Site
    Buenos Aires, 1221, Argentina
  • GSK Investigational Site
    Buenos Aires, 1437, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    Santa Fe, 3000, Argentina
  • GSK Investigational Site
    Tucuman, 4000, Argentina
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • GSK Investigational Site
    Florianopolis, Santa Catarina, Brazil
  • GSK Investigational Site
    Santo Andre, São Paulo 09060-670, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20221-903, Brazil
  • GSK Investigational Site
    São Paulo, 04079002, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1K3, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1C 2Z3, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2C 2N9, Canada
  • GSK Investigational Site
    Newmarket, Ontario L3Y 5G8, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1H 7K4, Canada
  • GSK Investigational Site
    Toronto, Ontario M9V 4B4, Canada
  • GSK Investigational Site
    Saint Leonard, Quebec H1S 3A9, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1W 4R4, Canada
  • GSK Investigational Site
    St-Romuald, Quebec G6W 5M6, Canada
  • GSK Investigational Site
    Quezon City, 1101, Philippines
  • GSK Investigational Site
    Quezon City, 1109, Philippines
09

References and documents

Publications

  • Anderson WH, Koshy BT, Huang L, Mosteller M, Stinnett SW, Condreay LD, Ortega H. Genetic analysis of asthma exacerbations. Ann Allergy Asthma Immunol. 2013 Jun;110(6):416-422.e2. doi: 10.1016/j.anai.2013.04.002. PubMed 23706709 ↗
  • Kerwin E, Prazma CM, Sutton L, Stempel DA. Safety and efficacy of long-term treatment with fluticasone propionate and salmeterol via DISKUS versus fluticasone propionate alone. Clin Res Reg Aff 2011;28(1):14-21.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2007
First posted
Mar 27, 2007
Start
May 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Feb 15, 2010
Last update
Dec 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00452348
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 27, 2007
Start date
May 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Feb 15, 2010
Last update
Dec 9, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion